GlassScriptPhysician profile
Dayna A Hawk
NPI 1679824825
$6,345.98
in general payments reported to CMS, 2019-2025
26 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,452 · 2022: $1,181 · 2023: $1,573 · 2024: $1,050 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $892.53 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $709.08 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $698.38 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $589.42 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Axsome Therapeutics, INC. | $466.97 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $444.81 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $357.33 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $316.98 | 2022-2024 | Jornay Pm |
| Bausch Health US, LLC | $229.37 | 2021-2025 | Aplenzin |
| Lundbeck LLC | $228.70 | 2021-2025 | Rexulti |
| Neos Therapeutics, LP | $216.77 | 2021-2023 | Adzenys Xr-Odt |
| Corium, LLC | $197.53 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $155.35 | 2021-2024 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $154.57 | 2021-2023 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.80 | 2022-2024 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $109.01 | 2021-2022 | |
| Noven Therapeutics, LLC | $96.72 | 2024-2025 | Xelstrym, Secuado |
| Adlon Therapeutics L.P. | $95.68 | 2021 | |
| Janssen Pharmaceuticals, INC | $68.46 | 2022-2025 | Spravato |
| Merck Sharp & Dohme LLC | $47.62 | 2022-2023 | Belsomra |
| Alfasigma USA, INC. | $33.43 | 2021 | |
| Collegium Pharmaceutical, INC. | $30.39 | 2025 | Jornay Pm |
| Biogen, INC. | $23.86 | 2024 | Zurzuvae |
| Harmony Biosciences LLC | $21.73 | 2024 | |
| Aytu Biopharma, INC. | $21.09 | 2021 | |
| Almatica Pharma LLC | $15.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dayna Hawk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.